Eric Schmidt

Stock Analyst at Cantor Fitzgerald

(0)
# 4660
Out of 5,296 analysts
50
Total ratings
21.88%
Success rate
-22.13%
Average return
21 Stocks
Name Action Price Target Current % Upside Ratings Updated
SMMT Summit Therapeutics
Reiterates: Overweight
n/a
n/a n/a 2 Apr 23, 2025
IMTX Immatics
Reiterates: Overweight
n/a
n/a n/a 4 Apr 1, 2025
GLYC GlycoMimetics
Initiates Coverage On: Overweight
n/a
n/a n/a 1 Mar 21, 2025
ALMS Alumis
Reiterates: Overweight
n/a
n/a n/a 4 Mar 20, 2025
BCAX Bicara Therapeutics
Reiterates: Overweight
14 14
15.65 -16.87% 2 Mar 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 2 Mar 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 1 Feb 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
n/a
n/a n/a 4 Feb 19, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Overweight
n/a
n/a n/a 1 Jan 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
n/a
n/a n/a 6 Jan 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 4 Dec 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 3 Dec 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
96 96
30.93 210.38% 4 Sep 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
n/a
n/a n/a 2 Sep 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 2 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
292 292
119.48 144.39% 3 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
370
492.94 -24.94% 1 Oct 17, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Oct 17, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
n/a
n/a n/a 1 Jul 10, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
31
n/a n/a 1 Jun 12, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
n/a
n/a n/a 1 May 30, 2017